Zacks Investment Research upgraded shares of ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) from a hold rating to a buy rating in a research note issued to investors on Tuesday, Zacks.com reports. They currently have $20.00 price objective on the stock.
According to Zacks, “Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan. “
ALPMY has been the subject of a number of other reports. ValuEngine downgraded shares of ASTELLAS PHARMA/ADR from a sell rating to a strong sell rating in a report on Friday, January 31st. Morgan Stanley started coverage on shares of ASTELLAS PHARMA/ADR in a report on Thursday, January 23rd. They issued an overweight rating for the company.
About ASTELLAS PHARMA/ADR
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent.
Further Reading: Are sell-side analysts objective?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ASTELLAS PHARMA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASTELLAS PHARMA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.